- Urocortin Arrests the Development of Parkinsonian-like Features in Rat via CRF-R1 Receptors
Abuirmeileh Amjad, Harkavyi Alex, Lever Rebecca, Biggs Christopher, Whitton Peter
- Urocortin attenuates key indicators of nigrostriatal pathway destruction in a rat hemiparkinsonian model
Biggs CS, Locke IC, Knight RA, Chowdrey HS, Whitton PS
- Urocortin reverses nigral da cell loss in 6-hydroxydopamine and lipopolysaccharide treated rats
Amjad Abuirmeileh, Christopher S. Biggs, Rebecca Lever and Peter S Whitton
- Urocortin reverses parkinsonian like effects of intra-nigral lipopolysaccharide injection
Amjad Abuirmeileh, Christopher S. Biggs, Rebecca Lever and Peter S Whitton1
- Urotensin stimulates GTPγ[35S] binding and increases intracellular calcium in chinese hamster ovary cells expressing the recombinant human urotensin II receptor
J McDonald; R Guerrini; G Calo; JP Thompson; DG Lambert
- Use of a 96-well plate method for the determination of von Willebrand factor activity in patient samples
Truss Nicola, Langley Katy, Pasi John, MacCallum Peter, Warner Tim
- Use of active and inactive stabilised versions of the A2A receptor to predict compound efficacy in vitro
Bennett KA, Tehan B, Lebon G, Tate CG, Langmead CJ
- Use of allopurinol in end-stage renal disease patients
Montane E, Arellano AL, Barriocanal A, Lopez A, Garcia F, Valderrama A, Costa J
- Use of a mathematical formula in association with the Evan’s Blue dye technique to quantify oedema formation in skin
X Kodji, P Thakore, AA Aubdool, J van Baardewijk, MA Fernandes, JE Keeble, SD Brain
- Use of an ex vivo Granulocyte Shape Change Assay to Determine Pharmacokinetic-Pharmacodynamic Relationship for CAM-3001, a New Antibody Therapy in Development for the Treatment of Rheumatoid Arthritis
Cohen Suzanne, McCourt Matthew, Monk Phillip, Meyers Tim, Appleton Emma, Wang Bing, Drinkwater Cathy, Nash Andrew, Anderson Ian, Sleeman Matthew
